Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more
Nektar Therapeutics - Asset Resilience Ratio
Nektar Therapeutics (NKTR) has an Asset Resilience Ratio of 76.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2024)
This chart shows how Nektar Therapeutics's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Nektar Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.18 Million | 76.05% |
| Total Liquid Assets | $229.18 Million | 76.05% |
Asset Resilience Insights
- Very High Liquidity: Nektar Therapeutics maintains exceptional liquid asset reserves at 76.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nektar Therapeutics Industry Peers by Asset Resilience Ratio
Compare Nektar Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Nektar Therapeutics (1997–2024)
The table below shows the annual Asset Resilience Ratio data for Nektar Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.43% | $210.97 Million | $303.85 Million | +2.02pp |
| 2023-12-31 | 67.42% | $268.34 Million | $398.03 Million | +8.77pp |
| 2022-12-31 | 58.65% | $416.75 Million | $710.60 Million | -4.79pp |
| 2021-12-31 | 63.44% | $708.74 Million | $1.12 Billion | +7.36pp |
| 2020-12-31 | 56.08% | $862.94 Million | $1.54 Billion | -6.05pp |
| 2019-12-31 | 62.13% | $1.23 Billion | $1.98 Billion | +9.09pp |
| 2018-12-31 | 53.04% | $1.14 Billion | $2.15 Billion | -4.22pp |
| 2017-12-31 | 57.26% | $291.37 Million | $508.87 Million | -0.66pp |
| 2016-12-31 | 57.92% | $329.46 Million | $568.87 Million | +7.45pp |
| 2015-12-31 | 50.47% | $253.37 Million | $502.06 Million | -0.59pp |
| 2014-12-31 | 51.05% | $225.46 Million | $441.62 Million | +5.50pp |
| 2013-12-31 | 45.56% | $197.96 Million | $434.53 Million | -5.02pp |
| 2012-12-31 | 50.57% | $251.76 Million | $497.79 Million | +13.34pp |
| 2011-12-31 | 37.24% | $225.86 Million | $606.55 Million | -19.97pp |
| 2010-12-31 | 57.21% | $298.18 Million | $521.23 Million | -3.02pp |
| 2009-12-31 | 60.23% | $346.61 Million | $575.52 Million | +20.37pp |
| 2008-12-31 | 39.86% | $223.41 Million | $560.54 Million | -16.14pp |
| 2007-12-31 | 56.00% | $406.06 Million | $725.10 Million | +4.60pp |
| 2006-12-31 | 51.40% | $394.88 Million | $768.18 Million | +26.37pp |
| 2005-12-31 | 25.03% | $214.93 Million | $858.55 Million | -17.16pp |
| 2004-12-31 | 42.20% | $314.33 Million | $744.92 Million | +6.22pp |
| 2003-12-31 | 35.98% | $221.92 Million | $616.79 Million | -6.73pp |
| 2002-12-31 | 42.71% | $259.09 Million | $606.64 Million | -4.28pp |
| 2001-12-31 | 46.99% | $313.54 Million | $667.24 Million | -8.42pp |
| 2000-12-31 | 55.41% | $348.83 Million | $629.54 Million | +9.22pp |
| 1999-12-31 | 46.19% | $104.75 Million | $226.81 Million | +3.10pp |
| 1998-12-31 | 43.08% | $57.95 Million | $134.50 Million | -28.08pp |
| 1997-12-31 | 71.16% | $85.22 Million | $119.76 Million | -- |